TY - JOUR
T1 - NMDA Inhibitors
T2 - A Potential Contrivance to Assist in Management of Alzheimer’s Disease
AU - Painuli, Sakshi
AU - Semwal, Prabhakar
AU - Zam, Wissam
AU - Taheri, Yasaman
AU - Ezzat, Shahira M.
AU - Zuo, Peijun
AU - Li, Liping
AU - Kumar, Dileep
AU - Sharifi-Rad, Javad
AU - Cruz-Martins, Natália
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that attracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, including AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.
AB - Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that attracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, including AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.
UR - https://www.scopus.com/pages/publications/85163920920
UR - https://www.scopus.com/pages/publications/85163920920#tab=citedBy
U2 - 10.2174/1386207325666220428112541
DO - 10.2174/1386207325666220428112541
M3 - Review article
C2 - 36476432
AN - SCOPUS:85163920920
SN - 1386-2073
VL - 26
SP - 2099
EP - 2112
JO - Combinatorial Chemistry and High Throughput Screening
JF - Combinatorial Chemistry and High Throughput Screening
IS - 12
ER -